Acushnet Holdings Corp. Announces Fourth-Quarter and Full Year 2016 Financial Results

News Release Available On www.AcushnetHoldingsCorp.com

FAIRHAVEN, Mass.--(BUSINESS WIRE)-- Acushnet Holdings Corp. (NYSE: GOLF) (“Acushnet”) published its fourth-quarter and full year 2016 financial results on March 22, 2017. The results are available via the Acushnet Investor Relations (http://www.acushnetholdingscorp.com/ir) and the U.S. Securities and Exchange Commision (https://www.sec.gov/cgi-bin/browse-edgar?company=acushnet&owner=exclude&action=getcompany) websites.

Acushnet will hold a conference call for investors at 8:30 a.m. ET on March 22 to review the fourth-quarter and full year 2016 financial results. A live webcast of that call will be available on the Acushnet Investor Relations website and a replay will be available shortly after the conclusion of the live event.

ABOUT ACUSHNET HOLDINGS CORP

We are the global leader in the design, development, manufacture and distribution of performance-driven golf products, which are widely recognized for their quality excellence. Driven by our focus on dedicated and discerning golfers and the golf shops that serve them, we believe we are the most authentic and enduring company in the golf industry. Our mission - to be the performance and quality leader in every golf product category in which we compete - has remained consistent since we entered the golf ball business in 1932. Today, we are the steward of two of the most revered brands in golf – Titleist, one of golf’s leading performance equipment brands, and FootJoy, one of golf’s leading performance wear brands. Additional information can be found at www.acushnetholdingscorp.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170322005552/en/

MEDIA CONTACT:
Joy Murphy, ICR
[email protected]

Source: Acushnet Holdings Corp.

You May Also Be Interested In

• Creatd files Form S-1 and reports Q1 2026 financial results
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• Silexion gets German approval to begin Phase 2/3 pancreatic cancer trial